{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Objective Response (OR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Complete Remission (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Partial Remission (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Marrow Complete Remission (mCR)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"This outcome measure presents overall Objective Response (CR+PR+mCR). Response to treatment was evaluated according to the International Working Group (IWG) 2006 criteria. Best response was tabulated from all available data, with each patient being classified into one of the categories defined in CR, PR, mCR.","groups":[{"description":"The patients received Volasertib 200 mg administered by Intravenous Infusion (IV) over 60 minutes on Day 1 and Day 15 of 28-day and Azacitidine 75 mg/m\\^2 administered by subcutaneous injection on days 1-7 of 28 day treatment cycle.","id":"OG000","title":"Volasertib 200 mg"}],"paramType":"NUMBER","populationDescription":"Treated Set (TS): This patient set included all patients who were dispensed study medication and were documented to have taken at least one dose of either Volasertib or Azacitidine.","reportingStatus":"POSTED","timeFrame":"Up to 9 months.","title":"Overall Objective Response (OR): Complete Remission (CR), Partial Remission (PR), or Marrow CR (mCR)","type":"SECONDARY","unitOfMeasure":"Participants"}